Drug interactions in dentistry: The importance of knowing your CYPs

Journal of the American Dental Association

Volumn 135, Issue 3, 2004, Pages 298-311

  Hersh, Elliot V ^a   Moore, Paul A ^b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DRUG;

DENTAL CARE; DRUG ANTAGONISM; DRUG INTERACTION; ENZYME INDUCTION; ENZYME SPECIFICITY; HUMAN; METABOLISM; PHARMACOKINETICS; REVIEW;

CYTOCHROME P-450 ENZYME SYSTEM; DENTAL CARE; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SUBSTRATE SPECIFICITY;

EID: 1942492548     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2004.0178     Document Type: Article

References (139)

1. Moore PA, Gage TW, Hersh EV, Yagiela JA, Haas DA. Adverse drug interactions in dental practice: professional and educational implications. JADA 1999;130:47-54.
2. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18:84-112.
3. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998;57:107-16.
4. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000;38:111-80.
5. Indiana University, School of Medicine, Division of Clinical Pharmacology. Cytochrome P450 drug interaction table. Available at: "medicine.iupui.edu/flockhart/table.htm". Accessed Aug. 23, 2003.
6. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1596-613.
7. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355(9203):547-8.
8. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
9. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998;46:101-10.
10. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69.
11. Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther 2003;73:529-37.
12. Bailey DG, Spence JD, Munoz C, Arnold JM. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991;337(8736):268-9.
13. Lown KS, Bailey DG, Fontana RJ, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 1997;99:2545-53.
14. Jackson DL, Johnson BS. Inhalation and enteral conscious sedation for the adult dental patient. Dent Clin North Am 2002;46:781-802.
15. Hersh EV. Adverse drug interactions in dental practice: interactions involving antibiotics, part II of a series. JADA 1999;130:236-51.
16. Moore PA. Adverse drug interactions in dental practice: interactions associated with local anesthetics, sedatives and anxiolytics, part IV of a series. JADA 1999;130:541-54.
17. Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 1993;53:298-305.
18. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, Vanakoski J. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol 1993;73:180-5.
19. Yasui N, Kondo T, Otani K, et al. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology (Berl) 1998;139:269-73.
20. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;55:481-5.
21. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 1994;56:601-7.
22. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000;67;335-41.
23. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-9.
24. Goho C. Oral midazolam-grapefruit juice drug interaction. Pediatr Dent 2001;23:365-6.
25. Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet 1998;23:55-9.
26. Beaver WT. Aspirin and acetaminophen as constituents of analgesic combinations. Arch Intern Med 1981;141:293-300.
27. McQuay H, Edwards J. Meta-analysis of single dose oral tramadol plus acetaminophen in acute postoperative pain. Eur J Anaesthesiol 2003;20(supplement 28):19-22.
28. Desmeules J, Gascon MP, Dayer P, Magistris M. Impact of environmental and genetic factors on codeine analgesia. Eur J Clin Pharmacol 1991;41:23-6.
29. Lee CR, McTavish D, Sorkin EM. Tramadol: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 1993;46:313-40.
30. Garrido MJ, Sayar O, Segura C, et al. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: role of cytochrome P450 2D activity. J Pharmacol Exp Ther 2003;305:710-8.
31. Orlando R, Piccoli P, De Martin S, Padrini R, Palatini P. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Br J Clin Pharmacol 2003;55:86-93.
32. Hiroi T, Ohishi N, Imaoka S, Yabusaki Y, Fukui H, Funae Y. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms. J Pharmacol Exp Ther 1995;272:939-44.
33. Hersh EV, Helpin ML, Evans OB. Local anesthetic mortality: report of case. ASDC J Dent Child 1991;58:489-91.
34. Moore PA. Preventing local anesthesia toxicity. JADA 1992;123:60-4.
35. Cooper SA. New peripherally-acting analgesic agents. Annu Rev Pharmacol Toxicol 1983;23:617-37.
36. Hersh EV, Moore PA, Ross GL. Over-the-counter analgesics and antipyretics: a critical assessment. Clin Ther 2000;22:500-48.
37. Kirchheiner J, Meineke I, Freytag G, Meisel C, Roots I, Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 2002;72:62-75.
38. Brenner SS, Herrlinger C, Dilger K, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib. Clin Pharmacokinet 2003;42:283-92.
39. Kirchheiner J, Meineke I, Steinbach N, Meisel C, Roots I, Brockmoller J. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br J Clin Pharmacol 2003;55:51-61.
40. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol 1997;52:293-8.
41. Jones A. Over-the-counter analgesics: a toxicology perspective. Am J Ther 2002;9:245-57.
42. The top 200 prescriptions for 2002 by number of U.S. prescriptions dispensed. Available at: "www.rxlist.com/top200.htm". Accessed July 16, 2003.
43. Prescott LF. Current status of issues concerning the safety of over-the-counter analgesics and nonsteroidal anti-inflammatory drugs. In: Rainsford KD, Powanda MC, eds. Safety and efficacy of non-prescription (OTC) analgesics and NSAIDs. Boston: Kluwer; 1998:1-9.
44. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 2002;40:3-20.
45. Rivera-Penera T, Gugig R, Davis J, et al. Outcome of acetaminophen overdose in pediatric patients and factors contributing to hepatotoxicity. J Pediatr 1997;130:300-4 .
46. Haas DA. Adverse drug interactions in dental practice: interactions associated with analgesics, part III in a series. JADA 1999;130:397-407.
47. Friedlander AH, Marder SR, Pisegna JR, Yagiela JA. Alcohol abuse and dependence: psychopathology, medical management and dental implications. JADA 2003;134:731-40.
48. Over-the-counter drug products containing analgesic/antipyretic active ingredients for internal use; required alcohol warning; final rule; compliance date. U.S. Food and Drug Administration, Department of Health and Human Services. Fed Regist 1999;64(51):13066-7.
49. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther 1996;60:241-6.
50. Rumack BH, Peterson RG. Acetaminophen overdose: incidence, diagnosis and management in 416 patients. Pediatrics 1978;62(5 pt 2 supplement):898-903.
51. Rumack BH, Peterson RC, Koch GG, Amara IA. Acetaminophen overdose: 662 cases with evaluation of oral acetylcysteine treatment. Arch Intern Med 1981;141(special issue 3):380-5.
52. Lyons L, Studdiford JS, Sommaripa AM. Treatment of acetaminophen overdosage with N-acetylcysteine. N Engl J Med 1997;296:174-5.
53. Dart RC, Kuffner EK, Rumack BH. Treatment of pain of fever with paracetamol (acetaminophen) in the alcoholic patient: a systemic review. Am J Ther 2000;7:123-34.
54. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Nonprescription Drugs Advisory Committee. Safety issues related to acetaminophen. Available at: "www.fda.gov/ohrms/dockets/ac/02/transcripts/ 3882T1.htm". Accessed July 20, 2003.
55. Trummel CL. Antiinflammatory drugs. In: Yagiela JA, Neidle EA, Dowd FJ, eds. Pharmacology and therapeutics for dentistry. 4th ed. St. Louis: Mosby; 1998:297-319.
56. Villikka K, Varis T, Backman JT, Neuvonen PJ, Kivisto KT. Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo. Eur J Clin Pharmacol 2001;57:457-60.
57. McCune JS, Hawke RL, LeCluyse EL, et al. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin Pharmacol Ther 2000;68:356-66.
58. LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy. J Allergy Clin Immunol 1983;72:34-9.
59. Fost DA, Leung DY, Martin RJ, Brown EE, Szefler SJ, Spahn JD. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. J Allergy Clin Immunol 1999;103:1031-5.
60. Glynn AM, Slaughter RL, Brass C, D'Ambrosio R, Jusko WJ. Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther 1986;39:654-9.
61. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther 1998;64:363-8.
62. Booker BM, Magee MH, Blum RA, Lates CD, Jusko WJ. Pharmacokinetic and pharmacodynamic interactions between diltiazem and methylprednisolone in healthy volunteers. Clin Pharmacol Ther 2002;72:370-82.
63. Varis T, Backman JT, Kivisto KT, Neuvonen PJ. Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone. Clin Pharmacol Ther 2000;67:215-21.
64. Varis T, Kivisto KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol 2000;56:489-93.
65. Loeffler PM. Oral benzodiazepines and conscious sedation: a review. J Oral Maxillofac Surg 1992;50:989-97.
66. Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther 1994;56:286-94.
67. Wenzel RG, Sarvis CA. Do butalbital-containing products have a role in the management of migraine? Pharmacotherapy 2002;22:1029-35.
68. Muller HP, Holderrieth S, Burkhardt U, Hoffler U. In vitro antimicrobial susceptibility of oral strains of Actinobacillus actinomycetemcomitans to seven antibiotics. J Clin Periodontol 2002;29:736-42.
69. Slots J. Selection of antimicrobial agents in periodontal therapy. J Periodontal Res 2002;37:389-98.
70. Slots J, Feik D, Rams TE. Prevalence and antimicrobial susceptibility of Enterobacteriaceae, Pseudomonadaceae and Acinetobacter in human periodontitis. Oral Microbiol Immunol 1990;5:149-54.
71. Batty KT, Davis TM, Ilett KF, Dusci LJ, Langton SR. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995;39:305-11.
72. Wijnands WJ, Vree TB, van Herwaarden CL. The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 1986;22:677-83.
73. Raaska K, Neuvonen PJ. Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia. Eur J Clin Pharmacol 2000;56:585-9.
74. Markowitz JS, Gill HS, Devane CL, Mintzer JE. Fluroquinolone inhibition of clozapine metabolism. Am J Psychiatry 1997;153:881.
75. Perkins DO. Predictors of noncompliance in patients with schizophrenia. J Clin Psychiatry 2002;63:1121-8.
76. Ciancio SG, van Winkelhoff AJ. Antibiotics in periodontal therapy. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:113-26.
77. Baumgartner JC. Antibiotics in endodontic therapy. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:143-55.
78. Peterson LJ. Antibiotics for oral and maxillofacial infections. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:157-73.
79. Beikler T, Flemmig TF. Antimicrobials in implant dentistry. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:195-211.
80. Kazmier FJ. A significant interaction between metronidazole and warfarin. Mayo Clin Proc 1976;51:782-4.
81. O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Eng J Med 1976;295:354-7.
82. Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 1988;28:240-5.
83. Kapseals dilantin (extended phenytoin sodium capsules, USP). In: Physicians' desk reference. 57th ed. Montvale, N.J.: Medical Economics; 2003:2531-3.
84. Montgomery EH. Antibacterial antibiotics. In: Yagiela JA, Neidle EA, Dowd FJ, eds. Pharmacology and therapeutics for dentistry. 4th ed. St. Louis: Mosby; 1998:496-533.
85. Montgomery EH. Antimicrobial agents in the prevention and treatment of infection. In: Yagiela JA, Neidle EA, Dowd FJ, eds. Pharmacology and therapeutics for dentistry. 4th ed. St. Louis: Mosby; 1998:634-43.
86. Honig P, Wortham D, Zamani K, Conner D, Cantilena L. Effect of erythromycin, clarithromycin and azithromycin on pharmacokinetics of terfenadine. Clin Pharmacol Ther 1993;53:161.
87. Matitila MJ, Vanakokski J, Idänpään-Heikkilä JJ. Azithromycin does not alter the effects of oral midazolam on human performance. Eur J Clin Pharmacol 1994;47:49-52.
88. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-5.
89. Sanz M, Herrera D. Individual drugs. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:33-52.
90. Honig PK, Woosley RL, Zamani K, Conner DP, Cantilena LR Jr. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1993;53:231-8.
91. Biglin KE, Faraon MS, Constance TD, Leih-Lai M. Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin. Ann Pharmacother 1994;28:282.
92. Kivisto KT, Neuvonen PJ, Klotz U. Inhibition of terfenadine metabolism: pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 1994;27:1-5.
93. Honig PK, Wortham DC, Zamani K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993;269:1513-8.
94. Honig PK, Wortham DC, Hull R, et al. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol 1993;33:1201-6.
95. Goss JE, Ramo BW, Blake K. Torsades de pointes associated with astemizole (Hismanal) therapy. Arch Intern Med 1993;153:2705.
96. Lefebvre RA, Van Peer A, Woestenborghs R. Influence of itraconazole on the pharmacokinetics and electrocardiographic effects of astemizole. Br J Clin Pharmacol 1997;43:319-22.
97. Kyrmizakis DE, Chimona TS, Kanoupakis EM, Papadakis CE, Velegrakis GA, Helidonis ES. QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. Am J Otolaryngol 2002;23:303-7.
98. Piquette RK. Torsades de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999;33:22-6.
99. van Haarst AD, van't Klooster GA, van Gerven JM, et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin Pharmacol Ther 1998;64:542-6.
100. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999;65:10-20.
101. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med 1991;154:213-5.
102. Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82.
103. Lees RS, Lees AM. Rhabdomyolysis from the coadminsistration of lovastatin and the antifungal agent itraconazole. N Engl J Med 1995;333:664-5.
104. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatic acid. Clin Pharmacol Ther 1996;60:54-61.
105. Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998;63:332-41.
106. Mazzu AL, Lasseter KC, Shamblen EC, Agarwal V, Lettieri J, Sundaresen P. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000;68:391-400.
107. Bennett JC, Moreland LW. Musculoskeletal and connective tissue disease. In: Cecil RL, Andreoli TE, eds. Cecil essentials of medicine. 4th ed. Philadelphia: Saunders; 1997:921-7.
108. Shaukat A, Benekli M, Vladutiu GD, Slack JL, Wetzler M, Baer MR. Simvastatin-fluconazole causing rhabdomyolysis. Ann Pharmacother 2003;37:1032-5.
109. Liedholm H, Nordin G. Erythromycin-felodipine interaction. DICP 1991;25:1007-8.
110. Neuvonen PJ, Suhonen R. Itraconazole interacts with felodipine. J Am Acad Dermatol 1995;33:134-5.
111. Tailor SA, Gupta AK, Walker SE, Shear NH. Peripheral edema due to nifedipine-itraconazole interaction: a case report. Arch Dermatol 1996;132:350-2.
112. Jensen CW, Flechner SM, Van Buren CT, et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 1987;43:263-70.
113. Spicer ST, Liddle C, Chapman JR, et al. The mechanism of cyclosporine toxicity induced by clarithromycin. Br J Clin Pharmacol 1997;43:194-6.
114. Lampen A, Christians U, Guengerich FP, et al. Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 1995;23:1315-24.
115. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
116. Floren LC, Bekersky I, Benet LZ, et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin Pharmacol Ther 1997;62:41-9.
117. Soltero L, Carbajal H, Rodriguez-Montalvo C, Valdes A. Coadministration of tacrolimus and ketoconazole in renal transplant recipients: cost analysis and review of metabolic effects. Transplant Proc 2003;35:1319-21.
118. Vasquez E, Pollak R, Benedetti E. Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant. 2001;15:95-9.
119. Bussey HI, Knodel LC, Boyle DA. Warfarin-erythromycin interaction. Arch Intern Med 1985;145:1736-7.
120. Hassell D, Utt JK. Suspected interaction: warfarin and erythromycin. South Med J 1985;78:1015-6.
121. Bachmann K, Schwartz JI, Forney R Jr, Frogameni A, Jauregui LE. The effect of erythromycin on the disposition kinetics of warfarin. Pharmacology 1984;28:171-6.
122. Recker MW, Kier KL. Potential interaction between clarithromycin and warfarin. Ann Pharmacother 1997;31:996-8.
123. Oberg KC. Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. Pharmacotherapy 1998;18:386-91.
124. Black DJ, Kunze KL, Wienkers LC, et al. Warfarin-fluconazole, part II: a metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996;24:422-8.
125. Berrettini WH. A case of erythromycin-induced carbamazepine toxicity. J Clin Psychiatry 1986;47:147.
126. Albani F, Riva R, Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia 1993;34:161-2.
127. O'Connor NK, Fris J. Clarithromycin-carbamazepine interaction in a clinical setting. J Am Board Fam Pract 1994;7:489-92.
128. Wong YY, Ludden TM, Bell RD. Effect of erythromycin on carbamazepine kinetics. Clin Pharmacol Ther 1983;33:460-4.
129. Miles MV, Tennison MB. Erythromycin effects on multiple-dose carbamazepine kinetics. Ther Drug Monit 1989;11:47-52.
130. Spina E, Arena D, Scordo MG, Fazio A, Pisani F, Perucca E. Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. Ther Drug Monit 1997;19:535-8.
131. Nair DR, Morris HH. Potential fluconazole-induced carbamazepine toxicity. Ann Pharmacother 1999;33:790-2.
132. Finch CK, Green CA, Self TH. Fluconazole-carbamazepine interaction. South Med J 2002;95:1099-100.
133. Tenenbein M. Theophylline toxicity due to drug interaction. J Emerg Med 1989;7:249-51.
134. Paulsen O, Hoglund P, Nilsson LG, Bengtsson HI. The interaction of erythromycin with theophylline. Eur J Clin Pharmacol 1987;32:493-8.
135. Wiggins J, Arbab O, Ayres JG, Skinner C. Elevated serum theophylline concentration following cessation of erythromycin treatment. Eur J Respir Dis 1986;68:298-300.
136. Richards W, Church JA, Brent DK. Theophylline-associated seizures in children. Ann Allergy 1985;54:276-9.
137. Iliopoulou A, Aldhous ME, Johnston A, Turner P. Pharmacokinetic interaction between theophylline and erythromycin. Br J Clin Pharmacol 1982;14:495-9.
138. Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996;276:912-7.
139. Fleischmann J. Topical and systemic antifungal and antiviral agents. In: Newman MG, van Winkelhoff AJ, eds. Antibiotic and antimicrobial use in dental practice. 2nd ed. Chicago: Quintessence; 2001:69-88.